MD

Manishaben Dhirajbhai Patel

Active Director Designated Partner DIN 08789610
DIN 08789610 First appointment Jul 2020 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2020
Shareholding value β€’β€’β€’β€’ Premium profile

About Manishaben Dhirajbhai Patel

Data last updated:

Manishaben Dhirajbhai Patel is a Designated Partner at Velocious Clinical Research Llp (since 2020). The company operates in Pharma.

DIN 08789610
Primary Designation Designated Partner
Industry Pharma
First Appointment 27 Jul 2020
Oldest Company Age 8 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner27 Jul 20202018Active

Board colleagues of Manishaben Dhirajbhai Patel

NameDINCompanyDesignation
Dhiraj Patel Manubhai08316867Velocious Clinical Research LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Velocious Clinical Research Llp
Premium access

Shareholding and investment profile for Manishaben Dhirajbhai Patel

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Manishaben Dhirajbhai Patel

Manishaben Dhirajbhai Patel currently holds 1 directorship: Velocious Clinical Research Llp (Designated Partner, since 27 Jul 2020).

Manishaben Dhirajbhai Patel was first appointed on 27 Jul 2020 as Designated Partner at Velocious Clinical Research Llp.

The current boards of Manishaben Dhirajbhai Patel's companies include Dhiraj Patel Manubhai (Velocious Clinical Research Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available